Tivdak and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Tivdak (tisotumab vedotin-tftv), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Norvasc, and have Cervix carcinoma.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Tivdak. It is created by eHealthMe based on reports of 326 people who have side effects when taking Tivdak from the FDA, and is updated regularly.

What is Tivdak?

Tivdak has active ingredients of tisotumab vedotin-tftv. eHealthMe is studying from 326 Tivdak users. Check the latest studies of Tivdak.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,516 drugs and 1,634 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 06, 2026

326 people reported to have side effects when taking Tivdak.
Among them, 12 people (3.68%) have Malignant neoplasm progression.

Could Tivdak cause Malignant neoplasm progression?

Among these 12 people:

How long have people been on Tivdak when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Tivdak? *

female: 100 %
male: 0.0 %

What is the age of people who have Malignant neoplasm progression when taking Tivdak? *

What are other drugs people take besides Tivdak? *

What are other side effects people have besides Malignant neoplasm progression? *

Cataract (clouding of the lens inside the eye): 2 people, 16.67%
Corneal Erosion (failure of the cornea's outermost layer of epithelial cells to attach to the underlying): 2 people, 16.67%
Vaginal Bleeding: 1 person, 8.33%
Dyspnea (difficult or laboured breathing): 1 person, 8.33%
Cervix Carcinoma (cancer of cervix): 1 person, 8.33%
Corneal Disorder: 1 person, 8.33%
Corneal Scar (nullah): 1 person, 8.33%
Death: 1 person, 8.33%
Drug Ineffective: 1 person, 8.33%
Eye Inflammation: 1 person, 8.33%

What are the existing conditions these people have? *

Stress And Anxiety: 2 people, 16.67%
Pain: 2 people, 16.67%
Nausea (feeling of having an urge to vomit): 2 people, 16.67%
Cervix Carcinoma Recurrent (repeated cancer of cervix): 2 people, 16.67%
Cervix Carcinoma (cancer of cervix): 2 people, 16.67%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 8.33%
Adenocarcinoma Of The Cervix (cervical cancer): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Tivdak and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tivdak:

Tivdak (326 reports)

Browse all side effects of Tivdak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,516 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,634 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tisotumab vedotin-tftv (the active ingredients of Tivdak) and Tivdak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.